SpyGlass Pharma (SGP) investor relations material

Executive summary

• Completed IPO in February 2026, raising $172.5 million in gross proceeds at $16.00 per share.

• Lead product candidate, BIM-IOL System, is in Phase 3 trials for glaucoma and ocular hypertension, with enrollment expected to complete in 2027 and NDA submission planned for 2028.

• Topline 12-month Phase 1/2 data showed 98% of patients eliminated IOP-lowering eye drops and achieved a 34% mean IOP reduction at the commercial dose.

• The BIM-IOL System demonstrated vision outcomes equivalent to state-of-the-art IOLs and a favorable safety profile.

• No revenue generated to date; focus remains on R&D and clinical advancement.

Financial highlights

• Net loss for Q1 2026 was $13.8 million, up from $8.8 million in Q1 2025, driven by increased R&D and G&A expenses.

• Operating expenses rose 108% year-over-year to $15.4 million.

• Cash, cash equivalents, and short-term investments totaled $251.0 million as of March 31, 2026.

• Accumulated deficit reached $118.5 million as of March 31, 2026.

• Research and development expenses were $8.5 million and G&A expenses were $6.9 million for Q1 2026.

Outlook and guidance

• Current liquidity expected to fund operations through 2028.

• Anticipates continued increase in R&D and G&A expenses as Phase 3 trials progress and public company costs rise.

• Substantial additional capital will be required for commercialization and further development.

• Initiation of the first-in-human trial for the BIM-DRS is planned for the second half of 2026.

• Four-year efficacy and safety follow-up for the BIM-IOL System is expected in Q4 2026.